Organon & Co. (OGN) Competitors $14.72 +0.13 (+0.89%) (As of 11/20/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrends OGN vs. SMMT, MRNA, GMAB, RDY, PCVX, CTLT, SRPT, RVMD, QGEN, and ITCIShould you be buying Organon & Co. stock or one of its competitors? The main competitors of Organon & Co. include Summit Therapeutics (SMMT), Moderna (MRNA), Genmab A/S (GMAB), Dr. Reddy's Laboratories (RDY), Vaxcyte (PCVX), Catalent (CTLT), Sarepta Therapeutics (SRPT), Revolution Medicines (RVMD), Qiagen (QGEN), and Intra-Cellular Therapies (ITCI). These companies are all part of the "pharmaceutical products" industry. Organon & Co. vs. Summit Therapeutics Moderna Genmab A/S Dr. Reddy's Laboratories Vaxcyte Catalent Sarepta Therapeutics Revolution Medicines Qiagen Intra-Cellular Therapies Summit Therapeutics (NASDAQ:SMMT) and Organon & Co. (NYSE:OGN) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, media sentiment, valuation, community ranking, profitability, analyst recommendations, earnings and dividends. Does the media prefer SMMT or OGN? In the previous week, Organon & Co. had 2 more articles in the media than Summit Therapeutics. MarketBeat recorded 4 mentions for Organon & Co. and 2 mentions for Summit Therapeutics. Organon & Co.'s average media sentiment score of 0.92 beat Summit Therapeutics' score of 0.30 indicating that Organon & Co. is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Summit Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Organon & Co. 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more volatility & risk, SMMT or OGN? Summit Therapeutics has a beta of -0.92, meaning that its share price is 192% less volatile than the S&P 500. Comparatively, Organon & Co. has a beta of 0.84, meaning that its share price is 16% less volatile than the S&P 500. Which has stronger earnings & valuation, SMMT or OGN? Organon & Co. has higher revenue and earnings than Summit Therapeutics. Summit Therapeutics is trading at a lower price-to-earnings ratio than Organon & Co., indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSummit Therapeutics$700K19,616.12-$614.93M-$0.28-66.50Organon & Co.$6.41B0.59$1.02B$5.042.92 Do institutionals and insiders hold more shares of SMMT or OGN? 4.6% of Summit Therapeutics shares are held by institutional investors. Comparatively, 77.4% of Organon & Co. shares are held by institutional investors. 88.3% of Summit Therapeutics shares are held by company insiders. Comparatively, 1.4% of Organon & Co. shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Does the MarketBeat Community prefer SMMT or OGN? Summit Therapeutics received 282 more outperform votes than Organon & Co. when rated by MarketBeat users. Likewise, 58.06% of users gave Summit Therapeutics an outperform vote while only 34.00% of users gave Organon & Co. an outperform vote. CompanyUnderperformOutperformSummit TherapeuticsOutperform Votes29958.06% Underperform Votes21641.94% Organon & Co.Outperform Votes1734.00% Underperform Votes3366.00% Do analysts rate SMMT or OGN? Summit Therapeutics currently has a consensus target price of $34.75, indicating a potential upside of 86.63%. Organon & Co. has a consensus target price of $21.33, indicating a potential upside of 44.88%. Given Summit Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Summit Therapeutics is more favorable than Organon & Co..Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Summit Therapeutics 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.75Organon & Co. 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.50 Is SMMT or OGN more profitable? Organon & Co. has a net margin of 20.30% compared to Summit Therapeutics' net margin of 0.00%. Organon & Co.'s return on equity of 644.70% beat Summit Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Summit TherapeuticsN/A -85.42% -52.66% Organon & Co. 20.30%644.70%8.12% SummaryOrganon & Co. beats Summit Therapeutics on 12 of the 19 factors compared between the two stocks. Ad Wide Moat ResearchTrump said you could learn something from this manEarly Warning: A Deep Crack Is Forming In The US Economy Stocks are booming thanks to Trump’s landslide victory. Yet one former Trump advisor says the picture is less rosy than it seems. “I’ve found a deep crack forming in the foundations of the US economy,” he says. “And before too long, it could tear our country apart.” It’s critical you learn more today, BEFORE it impacts your money and your retirement. Here’s everything you need to know. Get Organon & Co. News Delivered to You Automatically Sign up to receive the latest news and ratings for OGN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart OGN vs. The Competition Export to ExcelMetricOrganon & Co.Pharmaceutical IndustryMedical SectorNYSE ExchangeMarket Cap$3.79B$6.41B$5.01B$19.89BDividend Yield7.45%8.11%5.21%3.54%P/E Ratio2.9210.02126.5242.58Price / Sales0.59318.981,203.9018.13Price / Cash2.9922.1633.3717.85Price / Book-54.545.464.685.59Net Income$1.02B$152.97M$118.36M$985.39M7 Day Performance-5.64%-4.33%-2.46%-0.19%1 Month Performance-16.38%-8.65%-4.06%0.14%1 Year Performance31.59%28.53%29.55%23.70% Organon & Co. Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)OGNOrganon & Co.4.7217 of 5 stars$14.73+0.9%$21.33+44.9%+31.6%$3.76B$6.26B2.9210,000SMMTSummit Therapeutics1.8653 of 5 stars$18.62-6.9%$34.75+86.6%+835.7%$14.75B$700,000.000.00105Analyst ForecastMRNAModerna4.6286 of 5 stars$36.94-0.9%$84.00+127.4%-53.2%$14.35B$6.85B0.005,600Analyst UpgradeAnalyst RevisionGMABGenmab A/S4.3073 of 5 stars$20.45-0.2%$45.20+121.0%-37.0%$13.53B$19.84B19.852,204RDYDr. Reddy's Laboratories1.3247 of 5 stars$14.30-0.3%$17.00+18.9%+5.9%$11.94B$299.87B22.7027,048PCVXVaxcyte3.2906 of 5 stars$85.96-1.3%$147.50+71.6%+67.2%$10.85BN/A0.00160CTLTCatalent3.03 of 5 stars$59.00+0.2%$63.40+7.5%+47.8%$10.71B$4.38B-26.1116,900SRPTSarepta Therapeutics4.9373 of 5 stars$110.86+4.0%$181.33+63.6%+33.5%$10.18B$1.64B88.691,314Analyst DowngradeGap UpRVMDRevolution Medicines2.7869 of 5 stars$57.07+1.1%$61.00+6.9%+162.6%$9.50B$11.58M0.00443QGENQiagen4.4347 of 5 stars$42.11+3.2%$50.88+20.8%+2.5%$9.31B$1.97B107.975,967Positive NewsHigh Trading VolumeITCIIntra-Cellular Therapies4.4721 of 5 stars$85.64+2.7%$97.23+13.5%+46.2%$8.84B$464.37M0.00560Positive News Related Companies and Tools Related Companies SMMT Alternatives MRNA Alternatives GMAB Alternatives RDY Alternatives PCVX Alternatives CTLT Alternatives SRPT Alternatives RVMD Alternatives QGEN Alternatives ITCI Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NYSE:OGN) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Organon & Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Organon & Co. With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
